TY - JOUR
T1 - Overview of anti-VEGF therapy and angiogenesis. Part 1
T2 - Angiogenesis inhibition in solid tumor malignancies.
AU - Ellis, Lee M.
AU - Rosen, Lee
AU - Gordon, Michael S.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2006/1
Y1 - 2006/1
N2 - Several new agents that target the vascular endothelial growth factor (VEGF) pathway and inhibit angiogenesis are emerging as promising therapies in multiple cancer types. Bevacizumab, a humanized monoclonal antibody to VEGF-A, is currently approved in combination with intravenous 5-fluorouracil-containing regimens for the first-line treatment of metastatic colorectal cancer and recently demonstrated clinically important results in combination with chemotherapy in patients with non-small cell lung cancer and metastatic breast cancer. Other anti-VEGF agents that have shown benefit in various cancer types will be discussed in this monograph. Despite the often striking results observed with anti-VEGF agents, several unanswered questions remain, such as the optimal duration of therapy and patient selection criteria. These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed.
AB - Several new agents that target the vascular endothelial growth factor (VEGF) pathway and inhibit angiogenesis are emerging as promising therapies in multiple cancer types. Bevacizumab, a humanized monoclonal antibody to VEGF-A, is currently approved in combination with intravenous 5-fluorouracil-containing regimens for the first-line treatment of metastatic colorectal cancer and recently demonstrated clinically important results in combination with chemotherapy in patients with non-small cell lung cancer and metastatic breast cancer. Other anti-VEGF agents that have shown benefit in various cancer types will be discussed in this monograph. Despite the often striking results observed with anti-VEGF agents, several unanswered questions remain, such as the optimal duration of therapy and patient selection criteria. These other issues, including the biologic rationale for anti-VEGF therapy, as well as recent clinical trial data with anti-VEGF agents in colorectal, pancreatic, lung, kidney, and brease cancers, are discussed.
UR - http://www.scopus.com/inward/record.url?scp=33645989446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645989446&partnerID=8YFLogxK
M3 - Article
C2 - 16562372
AN - SCOPUS:33645989446
SN - 1543-0790
VL - 4
SP - suppl 1-10; quz 11-12
JO - Clinical advances in hematology & oncology : H&O
JF - Clinical advances in hematology & oncology : H&O
IS - 1
ER -